New Genmab-deal with limited results
The recent partnership deal with a Swedish company will not make the Danish biotech company Genmab a great profit, but the deal is still better than status quo, the company’s Head of Investor Relations points out.
af KRESTEN MORTEN MUNKSGAARD
Genmab has not come into money, even though the company has made a partnership deal concerning the substance HuMax IL-8 with the Swedish company Cormorant Pharmaceuticals. In fact, the upfront and milestone payments on the deal are so moderate that they are hardly worth mentioning, says Head of Investor Relations in Genmab, Rachel Gravesen.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
